Home・Lista de Ações・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Abrir

33.07 -0.09

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

32.1

Máximo

33.58

Indicadores-chave
By Trading Economics
Rendimento	43M 13M
Vendas	29M 107M
EPS	0.25
Margem de lucro	12.139
Funcionários	524
EBITDA	25M 17M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+111.53% upside

Dividendos
By Acuity
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	200M 1.6B
Abertura anterior	33.16
Fecho anterior	33.07

Immunocore Holdings PLC ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2026, 19:51 UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

3 de ago. de 2026, 20:03 UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

31 de jul. de 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

28 de jul. de 2026, 19:56 UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

27 de jul. de 2026, 18:06 UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

24 de jul. de 2026, 15:26 UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

22 de jul. de 2026, 19:16 UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

21 de jul. de 2026, 21:01 UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

20 de jul. de 2026, 20:06 UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Comparação entre Pares

Variação de preço

Immunocore Holdings PLC ADR Previsão

Preço-alvo

By TipRanks

111.53% parte superior

Previsão para 12 meses

Média 68.6 USD 111.53%

Máximo 100 USD

Mínimo 35 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Immunocore Holdings PLC ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Immunocore Holdings PLC ADR - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.